Nuclear receptor-related 1 (Nurr1) is a promising candidate target for neurodegenerative disease treatment, however, the validation of their therapeutic potential remains underexplored due to a lack of high-quality chemical tools. Here, the authors develop Nurr1 agonists from amodiaquine by scaffold hopping and fragment growing, exhibiting nanomolar potency and efficient cellular target engagement, showing their potential as lead and chemical tools.
- Minh Sai
- Emily C. Hank
- Daniel Merk